Ligand Expects 2026 Revenue of $270M-$310M
Ligand Pharmaceuticals expects 2026 revenue of $270 million to $310 million, versus a FactSet estimate of $289.5 million.
Related stories
Hotman Reports Interim Operating Loss
Hotman reported a standalone interim operating loss, compared with an operating loss in the same period a year earlier. Its fiscal-year forecast calls for operating profit, up 7.9%
M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC
Hotman Reports Six-Month Parent Net Loss
Hotman reported a parent net loss compared with a larger loss a year earlier. It forecasts a profit for 2026/27, up 3.7%.
M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC
Tokai Tokyo Financial Holdings Reports Six-Month Group Recurring Profit Up 82.4%
Group recurring profit increased 82.4% over the six-month period.
M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC
Tokai Tokyo Financial Holdings Group Net Profit Rises 58% in Six Months
M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC
Tokai Tokyo Financial Holdings reports interim net profit of 101.65億円, up 58.0%
Tokai Tokyo Financial Holdings reported consolidated net profit of 101.65億円 for the interim period ended September, up 58.0%.
M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC
Tokai Tokyo Financial Holdings Reports 6-Month Group Operating Profit Up 77.0%
M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC